Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Export

@article{citeulike:1082447, abstract = {The p53 tumor suppressor retains its wild-type conformation and transcriptional activity in half of all human tumors, and its activation may offer a therapeutic benefit. However, p53 function could be compromised by defective signaling in the p53 pathway. Using a small-molecule MDM2 antagonist, nutlin-3, to probe downstream p53 signaling we find that the cell-cycle arrest function of the p53 pathway is preserved in multiple tumor-derived cell lines expressing wild-type p53, but many have a reduced ability to undergo p53-dependent apoptosis. Gene array analysis revealed attenuated expression of multiple apoptosis-related genes. Cancer cells with mdm2 gene amplification were most sensitive to nutlin-3 in vitro and in vivo, suggesting that MDM2 overexpression may be the only abnormality in the p53 pathway of these cells. Nutlin-3 also showed good efficacy against tumors with normal MDM2 expression, suggesting that many of the patients with wild-type p53 tumors may benefit from antagonists of the p53-MDM2 interaction.}, address = {Roche Research Center, Hoffmann-La Roche Inc., Nutley, NJ 07110, USA.}, author = {Tovar, C. and Rosinski, J. and Filipovic, Z. and Higgins, B. and Kolinsky, K. and Hilton, H. and Zhao, X. and Vu, B. T. and Qing, W. and Packman, K. and Myklebost, O. and Heimbrook, D. C. and Vassilev, L. T.}, citeulike-article-id = {1082447}, citeulike-linkout-0 = {http://dx.doi.org/10.1073/pnas.0507493103}, citeulike-linkout-1 = {http://www.pnas.org/cgi/content/abstract/103/6/1888}, citeulike-linkout-2 = {http://view.ncbi.nlm.nih.gov/pubmed/16443686}, citeulike-linkout-3 = {http://www.hubmed.org/display.cgi?uids=16443686}, day = {7}, doi = {10.1073/pnas.0507493103}, issn = {0027-8424}, journal = {Proc Natl Acad Sci U S A}, keywords = {discovery, drug, interaction, molecule, nutlin, p53, protein, small}, month = {February}, number = {6}, pages = {1888--1893}, posted-at = {2007-09-16 14:08:35}, priority = {0}, title = {Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.}, url = {http://dx.doi.org/10.1073/pnas.0507493103}, volume = {103}, year = {2006} }

TY - JOUR ID - citeulike:1082447 L3 - citeulike-article-id:1082447 N2 - The p53 tumor suppressor retains its wild-type conformation and transcriptional activity in half of all human tumors, and its activation may offer a therapeutic benefit. However, p53 function could be compromised by defective signaling in the p53 pathway. Using a small-molecule MDM2 antagonist, nutlin-3, to probe downstream p53 signaling we find that the cell-cycle arrest function of the p53 pathway is preserved in multiple tumor-derived cell lines expressing wild-type p53, but many have a reduced ability to undergo p53-dependent apoptosis. Gene array analysis revealed attenuated expression of multiple apoptosis-related genes. Cancer cells with mdm2 gene amplification were most sensitive to nutlin-3 in vitro and in vivo, suggesting that MDM2 overexpression may be the only abnormality in the p53 pathway of these cells. Nutlin-3 also showed good efficacy against tumors with normal MDM2 expression, suggesting that many of the patients with wild-type p53 tumors may benefit from antagonists of the p53-MDM2 interaction. IS - 6 JF - Proc Natl Acad Sci U S A SN - 0027-8424 AD - Roche Research Center, Hoffmann-La Roche Inc., Nutley, NJ 07110, USA. EP - 1893 TI - Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. VL - 103 SP - 1888 KW - discovery KW - drug KW - interaction KW - molecule KW - nutlin KW - p53 KW - protein KW - small AU - Tovar, C AU - Rosinski, J AU - Filipovic, Z AU - Higgins, B AU - Kolinsky, K AU - Hilton, H AU - Zhao, X AU - Vu, BT AU - Qing, W AU - Packman, K AU - Myklebost, O AU - Heimbrook, DC AU - Vassilev, LT PY - 2006/02/07/ UR - http://dx.doi.org/10.1073/pnas.0507493103 ER -